Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02089230
Title MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field